NAMSDL Case Law Update
Opioid
 

This issue of NAMSDL Case Law Update focuses on several recent court decisions involving the marketing, distributing, and prescribing of controlled substances, primarily opioids. The topics addressed include a recently filed request to transfer ongoing federal litigation concerning the marketing and distribution of opioids to one federal district judge for coordinated pre-trial proceedings and a bipartisan coalition of state attorneys general who are investigating the same issue. In addition, in the cases analyzed below, the respective courts: (1) uphold the decertification of a pharmaceutical company by the DEA for failing to report suspicious orders of controlled substances; (2) question whether an employer’s requirement that an employee disclose prescription medication violates the ADA; (3) deal with the intersection of workers compensation claims and (potential) opioid abuse; and (4) consider a pharmacist’s duty to a customer when faced with repeated requests to dispense high dosages of opioids. The court decisions originate from the District of Columbia, Idaho, New Mexico, Tennessee, Utah, and Washington. Within this Update, cases are divided by the type of court (federal or state) and then listed in approximate descending order of appellate level. Read more »

ADA AMERICANS WITH DISABILITIES ACT case law Caselaw duty issue newsletter Opioid OXYCONTIN PHARMACEUTICAL MANUFACTURER PHARMACIST PHARMACY PRESCRIPTION DRUG ABUSE SUSPICIOUS ORDER update WORKERS COMPENSATION

 

This issue of NAMSDL Case Law Update focuses on several ongoing cases related to the marketing, distribution and prescribing of controlled substances. Summarized cases include: (1) a lawsuit recently filed against the maker of OxyContin by a city in Washington State and (2) a federal appellate court decision upholding a doctor’s conviction for Controlled Substances Act violations. The next issues of the Case Law Update will focus on cases involving drugged driving, marijuana and novel psychoactive substances. Read more »

Case Law Caselaw Issue Newsletter Opioid OxyContin Pharmaceutical manufacturer prescribing practices Prescription drug abuse Suspicious order Update

1